From: deputyfife23x@gmail.com   
      
       
   Preclinical Research   
      
   Harvard-MIT institute partners with Google-backed Calico to study   
   aging-related diseases   
      
      
   By Zachary Brennan+ 18-Mar-2015    
   Last updated on 18-Mar-2015 at 15:35 GMT   
      
   The Broad Institute of MIT and Harvard has entered into a partnership with   
   Calico to study the biology and genetics of aging as part of early-stage drug   
   discovery efforts.    
      
   The partnership will support several efforts at the institute to advance the   
   understanding of age-related diseases and to propel the translation of these   
   findings into new therapies.   
      
   As part of the collaboration, Calico will leverage the institute's genetics   
   and biology expertise and novel drug-discovery tools. Both Calico and the   
   Broad Institute refused to offer any more details about the partnership.   
      
   Eric Lander, President and Director of the Broad Institute said in a   
   statement: "The combination of our genetics, biology and chemistry expertise   
   with Calico's therapeutics expertise will accelerate progress on important   
   problems."   
      
   "This alliance is a key part of Calico's strategy to bring the best   
   cutting-edge science to bear on problems of aging. The Broad Institute is one   
   of the nation's preeminent research organizations whose outstanding research   
   has repeatedly revealed    
   fundamental mechanisms of the biology and genetics of disease," said Art   
   Levinson, CEO of Calico.   
      
   Calico is the Google-backed life sciences company led by Levinson, former   
   Chairman and CEO of Genentech, and Hal Barron, former EVP and Chief Medical   
   Officer of Genentech.   
      
   "Broad scientists have led the way in describing the genetics underlying many   
   of the common diseases of aging, including heart disease, diabetes, and   
   cancer, and we look forward to collaborating with them. We are very excited by   
   the opportunity to apply    
   their insights to develop new medicines for patients with these devastating   
   diseases," added Barron, who's now President of Research and Development at   
   Calico.   
      
   The Broad Institute was launched in 2004 to empower scientists to transform   
   medicine. The Broad Institute seeks to describe all the molecular components   
   of life and their connections; discover the molecular basis of major human   
   diseases; develop    
   effective new approaches to diagnostics and therapeutics; and disseminate   
   discoveries, tools, methods and data openly to the entire scientific community.   
      
   Back in April the institute signed on to collaborate with Pfizer and EMD   
   Serono to help profile the genomes of lupus patients as part of a broader plan   
   to find diagnostic approaches for disease monitoring. A philanthropist in July   
   also gifted the    
   institute $650m to galvanize research on psychiatric disorders.   
      
   Related News23andMe will move beyond personal genetic testing and into drug   
   R&D (Image: Adrienne Yancey/Opensource)   
   Google-backed 23andMe puts gene tech to work in drug discovery   
   San Diego convention centre hosts SOT 2015   
   Ebola, eCigarettes and microbiomes: Hot topics at Society of Toxicology annual   
   meeting   
   Google launches life sci unit as standalone firm   
   Google launches life sci unit as standalone Alphabet company   
   Broad Institute to sequence genomes for Pfizer-EMD Lupus research   
   Broad Institute to sequence genomes for Pfizer-EMD Lupus research   
   The license from the Broad Institute will expand GE's preclinical models.   
   GE Healthcare licenses CRISPR gene-snipping tool from Broad Institute   
   In the last five years, the understanding of the biological causes of mental   
   illnesses such as schizophrenia and bipolar disorder has accelerated   
   Philanthropist gives $650m to Broad Institute for psychiatric research   
   Related Products   
   Connect with Oracle at PCT Europe: Transform Clinical R&D from Pipeline to   
   Patient    
   Oracle Health Sciences | Research study - PDF file   
   PEPTIDES & OLIGONUCLEOTIDES    
   SANOFI - CEPiA | Technical / white paper - PDF file   
   Innovative Solutions for Biologics Utilizing Advanced Aseptic Processing    
   Catalent | Insight guide - PDF file   
   Alzheimer's Disease and patient recruitment    
   CCBR COMPANY INFORMATION | Research study - PDF file   
   Excellence in Pharmaceutical Analysis    
   Butterworth | Product brochure - PDF file   
      
      
      
      
   http://mobile.outsourcing-pharma.com/Preclinical-Research/Harvar   
   -MIT-institute-partners-with-Google-backed-Calico-to-study-aging   
   related-diseases   
      
   --- SoupGate-Win32 v1.05   
    * Origin: you cannot sedate... all the things you hate (1:229/2)